AstraZeneca Says Aspirin Behind Difference in Brilinta Treatment Effect

AstraZeneca has replied to a complete response letter on its blood-thinner Brilinta, providing supplementary analyses of its PLATO trial that focus on interactions between the drug and high-dose aspirin. These analyses support the hypothesis that an underlying interaction between Brilinta (ticagrelor) and higher doses of aspirin are likely behind the apparent difference in treatment effect observed in U.S. and non-U.S. patient subsets in PLATO, the company said. The PLATO trial was a head-to-head study of Brilinta versus Bristol-Myers Squibb/Sanofi-Aventis’ Plavix (clopidogrel).
Drug Industry Daily